首页> 外文期刊>Expert opinion on drug delivery >Application of PLGA nano/microparticle delivery systems for immunomodulation and prevention of allotransplant rejection
【24h】

Application of PLGA nano/microparticle delivery systems for immunomodulation and prevention of allotransplant rejection

机译:PLGA纳米/微粒输送系统在免疫调节和预防分征抑制中的应用

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: Allograft transplantation is an effective end-point therapy to replace the function of an impaired organ. The main problem associated with allotransplantation is the induction of immune responses that results in acute and chronic graft rejection. To modulate the response of the immune system, transplant recipients generally take high dose immunosuppressant drugs for life. These drugs are associated with serious side effects such as infection with opportunistic pathogens and the development of neoplasia. Areas covered: We reviewed the obstacles to successful transplantation and PLGA-based strategies to reduce immune-mediated allograft rejection. Expert opinion: Biomaterial-based approaches using micro- and nanoparticles such as poly (lactic-co-glycolic acid) (PLGA) can be used to achieve controlled release of drugs. This approach decreases the required effective dose of drugs and enables local delivery of these agents to specific tissues and cells, whilst decreasing systemic effects.
机译:介绍:同种异体移植移植是一种有效的终点治疗,以取代受损器官的功能。与同种异体持续相关的主要问题是导致急性和慢性接枝排斥反应的免疫应答的诱导。为了调节免疫系统的响应,移植受者通常服用高剂量免疫抑制药物。这些药物与严重的副作用有关,例如用机会主义病原体感染和肿瘤的发育。所涵盖的区域:我们审查了成功移植和基于PLGA的策略的障碍,以减少免疫介导的同种异体移植排斥反应。专家意见:使用微型和纳米颗粒如聚(乳酸 - 共乙醇酸)(PLGA)的基于生物材料的方法可用于实现药物的控释。这种方法降低了所需的有效剂量的药物,并使这些药剂局部递送至特定组织和细胞,同时降低全身效应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号